Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. An important implication of this disease is the progression of the disease to a more complicated condition called non-alcoholic steatohepatitis (NASH) and the wide variety of clinical presentations. Over the past 5 years, remarkable progresses have been made in understanding the genetic basis for the disease. Recent clinical trials in pharmacotherapy for the disease have been encouraging as well. It is anticipated that the integration of the wide spectrum information retrieved from genomics, transcriptomics and proteomics studies conducted in NAFLD and NASH will mediate a better understanding of the disease pathogenesis and facilitate the postulation of disease pathobiology pathways. Genetic and biological markers identified from the omics studies may hold promise for diagnosis, personalized treatment, early prevention and new drug development.

中文翻译：

---

非酒精性脂肪肝：疾病发病机制、治疗和诊断的当前观点和未来方向。

非酒精性脂肪肝（NAFLD）是世界上最常见的肝脏疾病之一。这种疾病的一个重要意义是疾病进展为一种更复杂的疾病，称为非酒精性脂肪性肝炎 (NASH)，并且临床表现多种多样。在过去的 5 年中，在了解该疾病的遗传基础方面取得了显着进展。最近对这种疾病进行药物治疗的临床试验也令人鼓舞。预计从 NAFLD 和 NASH 中进行的基因组学、转录组学和蛋白质组学研究中检索到的广谱信息的整合将有助于更好地了解疾病发病机制并促进疾病病理生物学途径的假设。